Background The aim of the present retrospective study was to analyze

Background The aim of the present retrospective study was to analyze medical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal malignancy (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. median PFS in individuals with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs… Continue reading Background The aim of the present retrospective study was to analyze